JP2020536068A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536068A5 JP2020536068A5 JP2020517983A JP2020517983A JP2020536068A5 JP 2020536068 A5 JP2020536068 A5 JP 2020536068A5 JP 2020517983 A JP2020517983 A JP 2020517983A JP 2020517983 A JP2020517983 A JP 2020517983A JP 2020536068 A5 JP2020536068 A5 JP 2020536068A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- weeks
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 201000011510 cancer Diseases 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 11
- 229960003301 nivolumab Drugs 0.000 claims description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 8
- 230000002411 adverse Effects 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 229940127089 cytotoxic agent Drugs 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 238000001802 infusion Methods 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 229910052697 platinum Inorganic materials 0.000 claims description 4
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 230000000259 anti-tumor effect Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- 239000012458 free base Substances 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 2
- 229960005386 ipilimumab Drugs 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 230000004083 survival effect Effects 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 206010027476 Metastases Diseases 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 238000002203 pretreatment Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 18
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- KRTIYQIPSAGSBP-KLAILNCOSA-N C[C@H](C(CC1)CCC1c1c(cc(cc2)F)c2ncc1)C(Nc(cc1)ccc1Cl)=O Chemical compound C[C@H](C(CC1)CCC1c1c(cc(cc2)F)c2ncc1)C(Nc(cc1)ccc1Cl)=O KRTIYQIPSAGSBP-KLAILNCOSA-N 0.000 description 1
- 206010059282 Metastases to central nervous system Diseases 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762565819P | 2017-09-29 | 2017-09-29 | |
| US62/565,819 | 2017-09-29 | ||
| US201762569766P | 2017-10-09 | 2017-10-09 | |
| US62/569,766 | 2017-10-09 | ||
| US201762580219P | 2017-11-01 | 2017-11-01 | |
| US62/580,219 | 2017-11-01 | ||
| US201762609210P | 2017-12-21 | 2017-12-21 | |
| US62/609,210 | 2017-12-21 | ||
| US201862642711P | 2018-03-14 | 2018-03-14 | |
| US62/642,711 | 2018-03-14 | ||
| US201862678490P | 2018-05-31 | 2018-05-31 | |
| US62/678,490 | 2018-05-31 | ||
| PCT/US2018/053443 WO2019067913A1 (en) | 2017-09-29 | 2018-09-28 | COMPOSITIONS AND METHODS OF TREATING CANCER |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020536068A JP2020536068A (ja) | 2020-12-10 |
| JP2020536068A5 true JP2020536068A5 (enExample) | 2021-11-04 |
| JP7341130B2 JP7341130B2 (ja) | 2023-09-08 |
Family
ID=65902748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517983A Active JP7341130B2 (ja) | 2017-09-29 | 2018-09-28 | 癌を治療するための組成物および治療方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11351163B2 (enExample) |
| EP (1) | EP3691643B1 (enExample) |
| JP (1) | JP7341130B2 (enExample) |
| KR (1) | KR102760684B1 (enExample) |
| CN (1) | CN111386117A (enExample) |
| WO (1) | WO2019067913A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9856320B2 (en) * | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| WO2016176503A1 (en) | 2015-04-28 | 2016-11-03 | Bristol-Myers Squibb Company | Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody |
| EP3288980B1 (en) * | 2015-04-28 | 2021-03-10 | Bristol-Myers Squibb Company | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
| US20240091351A1 (en) * | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| ES2706547T3 (es) | 1998-12-23 | 2019-03-29 | Pfizer | Anticuerpos monoclonales humanos para CTLA-4 |
| ES2539411T3 (es) | 1999-08-23 | 2015-06-30 | Dana-Farber Cancer Institute, Inc. | PD-1, receptor para la B7-4 y su utilización |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| AU2001233027A1 (en) | 2000-01-27 | 2001-08-07 | Genetics Institute, Llc | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| PT2170959E (pt) | 2007-06-18 | 2014-01-07 | Merck Sharp & Dohme | Anticorpos para o receptor humano de morte programada pd-1 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| ES2699965T3 (es) | 2011-03-10 | 2019-02-13 | Provectus Pharmatech Inc | Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
| CA3175360C (en) | 2013-05-31 | 2024-05-28 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| SMT202300039T1 (it) | 2013-09-13 | 2023-03-17 | Beigene Switzerland Gmbh | Anticorpi anti-pd1 e loro uso come terapia e per diagnostica |
| CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| US10570202B2 (en) * | 2014-02-04 | 2020-02-25 | Pfizer Inc. | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer |
| JP2017515859A (ja) * | 2014-05-15 | 2017-06-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置 |
| UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| AR102537A1 (es) | 2014-11-05 | 2017-03-08 | Flexus Biosciences Inc | Agentes inmunomoduladores |
| CA2971734C (en) | 2014-12-22 | 2025-11-18 | Pd-1 Acquisition Group, Llc | Anti-pd-1 antibodies |
| DK3303394T3 (da) | 2015-05-29 | 2020-07-06 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
| WO2016197367A1 (en) | 2015-06-11 | 2016-12-15 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| WO2017020291A1 (en) | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| MX392711B (es) | 2015-08-11 | 2025-03-24 | Wuxi Biologics Ireland Ltd | Anticuerpos anti-pd-1 novedosos. |
| WO2017024515A1 (en) | 2015-08-11 | 2017-02-16 | Wuxi Biologics (Cayman) Inc. | Novel anti-pd-1 antibodies |
| JP6869987B2 (ja) | 2015-09-01 | 2021-05-12 | アジェナス インコーポレイテッド | 抗ｐｄ−１抗体及びその使用方法 |
| CN108472245A (zh) * | 2015-11-04 | 2018-08-31 | 因赛特公司 | 用于吲哚胺2,3-双加氧酶抑制及其适应症的药物组合物和方法 |
| CN108367069B (zh) | 2015-12-14 | 2022-08-23 | 宏观基因有限公司 | 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法 |
| JP7082051B2 (ja) | 2016-01-11 | 2022-06-07 | アルモ・バイオサイエンシーズ・インコーポレイテッド | 抗原特異的ｃｄ８＋ｔ細胞の産生におけるインターロイキン－１０及びその使用方法 |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| US10731128B2 (en) * | 2016-11-22 | 2020-08-04 | Alloplex Biotherapeutics, Inc. | Compositions and methods for in vitro activation and expansion of serial killer T cell populations and passive immunization of a cancer patient with tumor cell killing cells |
-
2018
- 2018-09-28 US US16/649,277 patent/US11351163B2/en active Active
- 2018-09-28 JP JP2020517983A patent/JP7341130B2/ja active Active
- 2018-09-28 CN CN201880077408.5A patent/CN111386117A/zh active Pending
- 2018-09-28 EP EP18861598.3A patent/EP3691643B1/en active Active
- 2018-09-28 WO PCT/US2018/053443 patent/WO2019067913A1/en not_active Ceased
- 2018-09-28 KR KR1020207011965A patent/KR102760684B1/ko active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022088662A (ja) | ツカレゾールまたはそのアナログを含む組成物 | |
| JP2019517549A5 (enExample) | ||
| US9682082B2 (en) | Combinations of AKT and MEK inhibitor compounds, and methods of use | |
| JP2025185043A (ja) | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 | |
| US12116363B2 (en) | Combinations for immune-modulation in cancer treatment | |
| JP6410795B2 (ja) | カルボキシアミドトリアゾールオロテートを使用する、先の化学療法薬および標的薬物に対する獲得耐性を持つ癌を治療するための方法および組成物 | |
| TW201244714A (en) | PARP inhibitors for the treatment of CIPN | |
| WO2014142220A1 (ja) | 抗腫瘍剤 | |
| JP2018519324A5 (enExample) | ||
| CA2939464A1 (en) | Use of anti-ccr5 antibodies in graft versus host disease | |
| JP2016529285A5 (enExample) | ||
| MX2013013014A (es) | Metodo para el tratamiento de tumores solidos avanzados. | |
| JP2014513089A5 (enExample) | ||
| RU2020122083A (ru) | Способ снижения ототоксичности у педиатрических пациентов, получающих химиотерапию препаратами платины | |
| US20190134034A1 (en) | Method of Treating Liver Cancer | |
| US20180221382A1 (en) | Inhibition of mk2 in the treatment of cancer | |
| TW201141473A (en) | Combination therapy for small cell lung cancer | |
| JP2019524888A5 (enExample) | ||
| JP2021511344A5 (enExample) | ||
| EP2826482A1 (en) | Novel antitumor agent comprising combination of three agents | |
| JP2020528418A (ja) | ＢＥＴ阻害剤及びＢｃｌ−２阻害剤を用いた併用療法 | |
| TW201306833A (zh) | 包含康布列塔司他汀（ｃｏｍｂｒｅｔａｓｔａｔｉｎｓ）族衍生物及西妥昔單抗（ｃｅｔｕｘｉｍａｂ）之組合 | |
| US9566334B2 (en) | Combinations of a PI3K/AKT inhibitor compound with an HER3/EGFR inhibitor compound and use thereof in the treatment of a hyperproliferative disorder | |
| Zou et al. | Convection-enhanced delivery of sorafenib and suppression of tumor progression in a murine model of brain melanoma through the inhibition of signal transducer and activator of transcription 3 | |
| RS62560B1 (sr) | Antitumorski lek koji sadrži antitumorski kompleks platine, i pojačivač antitumorskog efekta |